Luke Miels had only been at the helm of GSK for 20 days before he signed off on his first multibillion-dollar buyout, and the ...

Amgen’s bad luck in lupus may finally be coming to an end. Daxdilimab, a monoclonal antibody acquired from Horizon ...

Beyond an oral version of its blockbuster weight loss drug Wegovy, which launched last month, Novo touted potential next-gen ...

England’s National Health Service’s faecal immunochemical test (FIT) has reduced referrals for suspected bowel cancer by ...

Before Pfizer closed its takeover, Metsera reported weight loss of up to 14.1% in a phase 2b trial of the weekly regimen.

While interested in CAR-T therapies’ potential to achieve durable, drug-free remission in serious autoimmune conditions, the ...

Exxel Pharma is eyeing a listing on the NYSE American to fund human trials for a drug class that has previously struggled to ...

National Institutes of Health Director Jayanta Bhattacharya, M.D., Ph.D., spent much of a Senate committee hearing dancing around direct answers—except when it came to vaccines, a topic in which he ...

As the Trump administration continues to pivot away from vaccinations, it is pushing for the development of new antiviral therapies via the launch of a $100 million competition. | While the Trump ...

A phase 2a trial of NMD Pharma’s rare disease prospect ignaseclant has missed its primary endpoint. | A phase 2a trial of NMD ...

Charles River Laboratories is continuing its run of layoffs by announcing the closure of its cell therapy contract development and manufacturing organization (CDMO) site in Hanover, Maryland that will ...

Quest Diagnostics has rolled out an ultrasensitive blood test to monitor multiple myeloma treatment, potentially sparing patients from more invasive and costly bone marrow aspirations. | Quest ...